Latest:
Dr Vonderheide on Responses With RAS(ON) Inhibition in Preclinical Pancreatic Cancer Models
Robert Herman Vonderheide, MD, DPhil, discussed potential immune responses with immunotherapy plus KRAS inhibition in pancreatic cancer models.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Pau Montesinos, MD, PhD
Latest:
Dr Montesinos on Quizartinib Plus Chemotherapy in Newly Diagnosed FLT3-ITD Wild-Type AML
Pau Montesinos, MD, PhD, discusses preliminary efficacy seen with the addition of quizartinib to standard 7+3 chemotherapy in patients with newly diagnosed FLT3-ITD wild-type acute myeloid leukemia.
Roxana S. Dronca, MD
Latest:
Comorbidities, Quality of Life, Efficacy, and Safety in Expanding Subcutaneous Treatment Use
Panelists discuss how subcutaneous checkpoint inhibitors are appropriate for nearly all patients except those with severe cachexia limiting injection sites, with patient conversations emphasizing equivalent efficacy data, safety profiles, quality of life benefits including potential home administration, and the option to maintain IV therapy for patients who prefer their current regimen.
N. Arvind Dasari, MD, MS
Latest:
Expert Perspectives on Balancing Therapy Decisions and Quality of Life in mCRC
Panelists discuss how immunotherapy generally provides better quality of life compared to traditional chemotherapy, particularly noting that microsatellite instability-high patients on immune checkpoint inhibitors report significantly better experiences than those on FOLFOX regimens.
Yong Jae Lee, MD, PhD
Yong Jae Lee, MD, PhD, is from the Yonsei University College of Medicine
Latest:
Dr Lee on the Preliminary Safety of Nivolumab for Resectable dMMR Endometrial Cancer
Yong Jae Lee, MD, PhD, discusses the clinical relevance of the preliminary safety of nivolumab for resectable mismatch repair–deficient endometrial cancer.
Craig Horbinski, MD, PhD
Latest:
Monitoring DMG Treatment Response Using RANO 2.0 Criteria
Experts discuss the evolution of the Response Assessment in Neuro-Oncology (RANO) criteria culminating in RANO 2.0, which standardizes treatment response evaluation for gliomas by refining imaging benchmarks, simplifying measurement methods, and addressing challenges in distinguishing progression from treatment effects to enhance consistency in both clinical trials and routine practice.
Karine Tawagi, MD
Karine Tawagi, MD, is a hematologist/oncologist and assistant professor of clinical medicine at the University of Illinois
Latest:
Urothelial ESMO 2025 Updates
OncLive partnered with Two Onc Docs to review updates from the 2025 ESMO Congress on bladder cancer management that may change guidelines.
Candice Schwartz, MD
Latest:
Biomarkers Drive ICIs in Colon Cancer
December 14, 2020 - Immunotherapy agents have shown efficacy in malignant melanoma, kidney cancer, and non–small cell lung cancer, and investigators are examining the efficacy of checkpoint inhibitors in less immunogenic tumors such as colon cancer, particularly in tumors with high microsatellite instability and deficient mismatch repair genes.
Rachel E. Sanborn, MD
Rachel E. Sanborn, MD, serves as the medical director of the Thoracic Oncology Program and the Phase I Clinical Trials Program at the Earle A. Chiles Research Institute at Providence Cancer Institute.
Latest:
Dr Sanborn on Early Efficacy and Safety Data With Sigvotatug Vedotin Plus Pembrolizumab in NSCLC
Rachel E. Sanborn, MD, discusses preclinical and early clinical data supporting the use of the IB6-directed ADC sigvotatug vedotin in patients with NSCLC.